Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01408043 · ClinicalTrials.gov registry record · NA
Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
A NA study, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- NA
- Development phase
- 25
- Enrollment target
NCT01408043 is a NA study that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 25 participants.
The verdict
NCT01408043, a NA study, was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
Study Summary
This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood so they can be collected and stored.
Interventions
- DRUG etoposide
- PROCEDURE leukapheresis
- BIOLOGICAL filgrastim
- DRUG plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01408043
The ClinicalTrials.gov registry entry for NCT01408043 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which etoposide is the first listed.
NCT01408043 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01408043 about?
NCT01408043 is a clinical study titled "Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma". This clinical trial studies etoposide, filgrastim and plerixafor in improving stem cell mobilization in patients with non-Hodgkin lymphoma. Giving colony-stimulating factors, such as filgrastim, and plerixafor and etoposide together helps stem cells move from the patient's bone marrow to the blood s...
What is the current status of trial NCT01408043?
This trial is currently terminated. It is a NA study. The enrollment target is 25 participants. The study started on 2011-10. Estimated completion is 2016-05.
What interventions are being tested in trial NCT01408043?
The interventions under investigation include: etoposide (DRUG), leukapheresis (PROCEDURE), filgrastim (BIOLOGICAL), plerixafor (DRUG).
Who is sponsoring clinical trial NCT01408043?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.